Skip to main content
Addgene

pSuper Retro GFP DGK alfa human
(Plasmid #224578)

Ordering

This material is available to academics and nonprofits only.
Item Catalog # Description Quantity Price (USD)
Plasmid 224578 Standard format: Plasmid sent in bacteria as agar stab 1 $85

Backbone

  • Vector backbone
    pSUPER Retro GFP
  • Backbone manufacturer
    Oligoengine
  • Backbone size w/o insert (bp) 8371
  • Vector type
    Retroviral, RNAi
  • Selectable markers
    Neomycin (select with G418)

Growth in Bacteria

  • Bacterial Resistance(s)
    Ampicillin, 100 μg/mL
  • Growth Temperature
    37°C
  • Growth Strain(s)
    NEB Stable
  • Copy number
    High Copy

Gene/Insert

  • Gene/Insert name
    sh RNAi Diacylglycerol kinase alfa human
  • gRNA/shRNA sequence
    GCCAGAAGACCATGGATGAttcaagagaTCATCCATGGTCTTCTGGC
  • Species
    H. sapiens (human)
  • Insert Size (bp)
    64
  • Entrez Gene
    DGKA (a.k.a. DAGK, DAGK1, DGK-alpha)
  • Promoter H1

Cloning Information

  • Cloning method Restriction Enzyme
  • 5′ cloning site Bgl2 (destroyed during cloning)
  • 3′ cloning site Hind3 (not destroyed)
  • 5′ sequencing primer pSuperRetro2
  • 3′ sequencing primer pSuperRetro 1
  • (Common Sequencing Primers)

Terms and Licenses

  • Academic/Nonprofit Terms
  • Industry Terms
    • Not Available to Industry
Trademarks:
  • Zeocin® is an InvivoGen trademark.
How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    pSuper Retro GFP DGK alfa human was a gift from Isabel Mérida (Addgene plasmid # 224578 ; http://n2t.net/addgene:224578 ; RRID:Addgene_224578)
  • For your References section:

    Diacylglycerol kinase alpha promotes 3D cancer cell growth and limits drug sensitivity through functional interaction with Src. Torres-Ayuso P, Daza-Martin M, Martin-Perez J, Avila-Flores A, Merida I. Oncotarget. 2014 Oct 30;5(20):9710-26. doi: 10.18632/oncotarget.2344. 10.18632/oncotarget.2344 PubMed 25339152